| Website | chemocentryx.com |
| Category | BioTech |
| Phone | 1-650-210-2900 |
| Employees | |
| Founded | 1997 |
| Description | ChemoKine therapuetics development |
| Total | $80.5M |
| Unattributed, 6/04 HBM BioVentures Alta Partners Gimv OrbiMed Advisors HealthCap | $33M |
| Series C, 8/06 Jennison Associates HBM BioVentures OrbiMed Advisors Techne Corporation Alta Partners Gimv | $17.7M |
| Series D, 3/07 Alta Partners Gimv HBM BioVentures OrbiMed Advisors Glaxo Group | $29.8M |
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
